Compare ALXO & CXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALXO | CXH |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 65.6M |
| IPO Year | 2020 | N/A |
| Metric | ALXO | CXH |
|---|---|---|
| Price | $1.42 | $7.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | ★ 303.0K | 25.9K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $6.41 |
| 52 Week High | $2.27 | $7.74 |
| Indicator | ALXO | CXH |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 46.09 |
| Support Level | $1.29 | $7.92 |
| Resistance Level | $1.56 | $8.01 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 47.83 | 22.22 |
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.